Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Authors
Discussion
Loading...
Member takes
Implication
Review reveals biological drivers of cognitive deficits in schizophrenia, highlighting novel therapeutic targets beyond current care.
Key Points
- To review the clinical characteristics, etiology, neural mechanisms, and developing therapeutic interventions for cognitive dysfunction in schizophrenia.
- Synthesized evidence on the clinical course, presentation, and shared genetic and environmental risk factors of cognitive deficits in schizophrenia.
- Reviewed neurochemical and cellular mechanisms, focusing on dopamine, cholinergic systems, and cortical microcircuit interactions.
- Cognitive impairment represents an untreated core feature of schizophrenia that substantially drives everyday functional disability despite current antipsychotic therapy.
- Underlying pathophysiology is governed by dysregulated dopamine and acetylcholine pathways alongside disrupted balance between inhibitory GABAergic interneurons and excitatory glutamatergic pyramidal cells.
- Targeted pharmacological approaches addressing these specific neurochemical circuits offer promising candidate avenues for novel treatment strategies.
Cite This Study
McCutcheon et al. (2023) studied this question.